STOCK TITAN
  1. Home
  2. News
  3. BMY

Bristol-Myers Squibb Co. - BMY STOCK NEWS

Welcome to our dedicated page for Bristol-Myers Squibb Co. news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co. stock.

Bristol-Myers Squibb Co. (BMY) is a renowned American multinational pharmaceutical company headquartered in New York City. As one of the largest pharmaceutical companies globally, Bristol-Myers Squibb (BMS) consistently ranks on the Fortune 500 list. In fiscal 2022, the company achieved total revenue of $46.2 billion.

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs across various therapeutic areas, including cardiovascular, cancer, and immune disorders. A significant area of focus for BMS is immuno-oncology, where it has established itself as a leader in drug development. Approximately 70% of BMS's total sales are derived from the U.S. market, reflecting its higher dependence on this region compared to its peers.

Recent achievements and collaborations highlight BMS's commitment to innovation and partnerships. On May 22, 2024, BMS joined NeoPhore Limited's oversubscribed Series B extension round. This additional investment will enable NeoPhore to explore novel biology associated with the DNA mismatch repair (MMR) pathway in cancer, and further advance its pre-clinical studies. NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients.

Another noteworthy collaboration was announced on June 5, 2024, with I-Mab, a U.S.-based global biotech company. This partnership will evaluate the combination of givastomig, an investigational Claudin 18.2 x 4-1BB bispecific antibody, with BMS's immune checkpoint inhibitor, nivolumab, and chemotherapy. The study, a multi-national Phase 1, will focus on advanced Claudin 18.2-positive gastric and esophageal cancers. BMS will supply nivolumab, which is designed to enhance T-cell function and improve anti-tumor responses.

Additionally, on June 5, 2024, Envisagenics, an AI-driven biotechnology company, announced a Series B fundraising round with participation from BMS. This funding will be utilized to further develop Envisagenics' pipeline of novel preclinical oncology assets using their cloud-based AI drug discovery platform, SpliceCore®. This collaboration underscores BMS's continued investment in innovative technologies and therapeutics.

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases. Through strategic partnerships, cutting-edge research, and a commitment to therapeutic advancements, BMS continues to make significant strides in the biopharmaceutical industry.

News

Bristol Myers Squibb Reports First Quarter Financial Results for 2024

Rhea-AI Summary
Bristol Myers Squibb reported first quarter financial results for 2024, showcasing a 5% increase in revenues to $11.9 billion. Key achievements include U.S. approval of Abecma and Breyanzi, positive proof of concept for Opdualag, and strategic cost-saving initiatives. Despite a GAAP loss per share of $(5.89), the non-GAAP loss per share was $(4.40). The company aims to reinvest cost savings to fuel innovation and growth.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.51%
Tags
earnings
-
News

Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster

Rhea-AI Summary
Bristol Myers Squibb and Cellares have entered into a $380M worldwide capacity reservation and supply agreement for the manufacture of CAR T cell therapies. Cellares will provide its Cell Shuttle platform for Bristol Myers Squibb's clinical and commercial-scale manufacturing needs, enhancing agility, scalability, and turnaround time. This collaboration aims to bring the promise of cell therapies to more patients faster.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
none
-
News

Building a Better Future: Bristol Myers Squibb 2023 ESG Report

Rhea-AI Summary
Bristol Myers Squibb (BMY) focuses on advancing patient health globally and enhancing ESG performance. The company aims to address health inequities, expand access to medicines in LMICs, and reduce environmental impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.33%
Tags
none
News

KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)

Rhea-AI Summary
Bristol Myers Squibb presents promising data on KRAZATI (adagrasib) in combination with cetuximab for KRASG12C-mutated colorectal cancer at AACR annual meeting. The study shows an objective response rate of 34%, with a median progression-free survival of 6.9 months and median overall survival of 15.9 months. Disease control was observed in 85% of patients, highlighting the potential of adagrasib for this specific patient group.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
-
News

Bristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals

Rhea-AI Summary
Bristol Myers Squibb (BMY) releases its 2023 Environmental, Social, and Governance (ESG) Report, highlighting progress in patient access, product innovation, and diversity. The company focuses on advancing patient health, scientific boundaries, and global workforce inclusivity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
none
-
News

Bristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

Rhea-AI Summary
Bristol Myers Squibb (BMY) reports positive interim results from the Phase 3 EMERGENT-4 trial evaluating the long-term efficacy of KarXT in patients with schizophrenia. More than 75% of participants showed significant improvement in symptoms over 52 weeks, with promising safety and tolerability profiles.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News

Bristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society

Rhea-AI Summary
Bristol Myers Squibb presents favorable long-term metabolic profile and safety data for KarXT in schizophrenia treatment at the Annual Congress of the Schizophrenia International Research Society.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News

U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy

Rhea-AI Summary
Abecma receives FDA approval for earlier use in treating relapsed or refractory multiple myeloma, demonstrating significant progression-free survival benefits and a well-established safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.16%
Tags
fda approval
-
News

European Commission Expands Approval of Bristol Myers Squibb’s Reblozyl® (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)

Rhea-AI Summary
Bristol Myers Squibb (BMY) receives expanded approval from the European Commission for Reblozyl (luspatercept) as a first-line treatment for adult patients with transfusion-dependent anemia due to myelodysplastic syndromes. The approval is based on the Phase 3 COMMANDS study, showing Reblozyl's superior efficacy over epoetin alfa in achieving transfusion independence and hemoglobin increase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.06%
Tags
none
News

Bristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals

Rhea-AI Summary
Bristol Myers Squibb (BMY) releases its 2023 ESG Report focusing on patient access, innovation, and diversity. The report highlights the company's progress, strategy, and goals in ESG initiatives.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.47%
Tags
none

FAQ

What is the current stock price of Bristol-Myers Squibb Co. (BMY)?

The current stock price of Bristol-Myers Squibb Co. (BMY) is $57.33 as of December 20, 2024.

What is the market cap of Bristol-Myers Squibb Co. (BMY)?

The market cap of Bristol-Myers Squibb Co. (BMY) is approximately 114.2B.

What is Bristol-Myers Squibb's core business?

Bristol-Myers Squibb focuses on discovering, developing, and marketing drugs for various therapeutic areas, including cardiovascular, cancer, and immune disorders.

Where is Bristol-Myers Squibb headquartered?

Bristol-Myers Squibb is headquartered in New York City, USA.

What was Bristol-Myers Squibb's revenue for fiscal 2022?

Bristol-Myers Squibb reported a total revenue of $46.2 billion for fiscal 2022.

What is a significant focus area for Bristol-Myers Squibb?

A significant focus area for Bristol-Myers Squibb is immuno-oncology, where it is a leader in drug development.

How much of Bristol-Myers Squibb's total sales come from the U.S. market?

Approximately 70% of Bristol-Myers Squibb's total sales are derived from the U.S. market.

What recent collaboration did Bristol-Myers Squibb announce with NeoPhore Limited?

On May 22, 2024, Bristol-Myers Squibb joined NeoPhore Limited's Series B extension round to explore novel biology associated with the DNA mismatch repair pathway in cancer.

What is the purpose of Bristol-Myers Squibb's collaboration with I-Mab?

The collaboration with I-Mab focuses on evaluating the combination of givastomig with BMS's nivolumab and chemotherapy for advanced Claudin 18.2-positive gastric and esophageal cancers.

What is SpliceCore®?

SpliceCore® is Envisagenics' cloud-based AI drug discovery platform that integrates machine learning algorithms to identify novel and disease-specific RNA splicing isoforms.

When did Bristol-Myers Squibb participate in Envisagenics' Series B fundraising round?

Bristol-Myers Squibb participated in Envisagenics' Series B fundraising round announced on June 5, 2024.

What is Bristol-Myers Squibb's mission?

Bristol-Myers Squibb's mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.

Stock BMY logo
Bristol-Myers Squibb Co.

NYSE:BMY

BMY Rankings

#110 Ranked by Market Cap
#708 Ranked by Dividends

BMY Stock Data

114.19B
2.03B
0.12%
78.46%
1.27%
Drug Manufacturers - General
Pharmaceutical Preparations
Link
United States of America
PRINCETON